Literature DB >> 12595956

Caffeine enhances myocardial uptake of idarubicin but reverses its negative inotropic effect.

Wonku Kang1, Michael Weiss.   

Abstract

Idarubicin (IDA) is a member of an important class of anticancer agents, the anthracycline antibiotics. Although the clinical efficacy of anthracyclines is limited by a high incidence of severe cardiac toxicity, our understanding of IDA transport into the heart is still limited. In a previous study, we demonstrated that IDA is transported into the heart by a saturable mechanism. Based on in vitro data suggesting an enhancement by methylxanthines of IDA influx in leukemia cells, this study was designed to test the hypothesis that a commonly used methylxanthine, caffeine, might influence the myocardial uptake of IDA. In the Langendorff rat heart, after infusion of 0.5 mg IDA during 10 min, the presence of caffeine (1 microM) in perfusate enhanced the residual amount of IDA in the heart by 30% due to a 2.7-fold increase in the maximal uptake rate V(max). Theophylline (3 micro M), in contrast, did not influence the uptake process but caused a slight decrease of fractional myocardial sequestration rate (19% reduction). Caffeine reversed the cardiodepressive action of IDA (49% decrease in left ventricular developed pressure at the end of infusion) to a positive inotropic effect (18% increase of basal level). Theophylline significantly attenuated the negative inotropic effect of IDA (only 21% decrease) and led to positive inotropism in the washout phase (21% increase at the end of experiment). We speculate that co-administration of caffeine may enhance the chronic cardiotoxicity of IDA by increasing its accumulation in the heart.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12595956     DOI: 10.1007/s00210-002-0683-2

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  15 in total

1.  Adriamycin causes dual inotropic effects through complex modulation of myocardial Ca2+ handling.

Authors:  T Matsushita; M Okamato; J Toyama; I Kodama; S Ito; T Fukutomi; S Suzuki; M Itoh
Journal:  Jpn Circ J       Date:  2000-01

2.  P-glycoprotein inhibitors enhance saturable uptake of idarubicin in rat heart: pharmacokinetic/pharmacodynamic modeling.

Authors:  Michael Weiss; Wonku Kang
Journal:  J Pharmacol Exp Ther       Date:  2002-02       Impact factor: 4.030

3.  Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit.

Authors:  M Looby; R Linke; M Weiss
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

4.  Mechanism of caffeine modulation of the antitumor activity of adriamycin.

Authors:  Y Sadzuka; E Mochizuki; Y Takino
Journal:  Toxicol Lett       Date:  1995-01       Impact factor: 4.372

5.  Determination of idarubicin and idarubicinol in rat plasma using reversed-phase high-performance liquid chromatography and fluorescence detection.

Authors:  O Kuhlmann; S Hofmann; M Weiss
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-05-28

6.  Caffeine-potentiated radiochemotherapy and function-saving surgery for high-grade soft tissue sarcoma.

Authors:  H Tsuchiya; N Yamamoto; N Asada; T Terasaki; Y Kanazawa; T Takanaka; H Nishijima; K Tomita
Journal:  Anticancer Res       Date:  2000 May-Jun       Impact factor: 2.480

7.  Ca2+ overloading causes the negative inotropic effect of doxorubicin in myocytes isolated from guinea-pig hearts.

Authors:  K Temma; A Chugun; T Akera; Y Hara; T Sasaki; H Kondo
Journal:  Eur J Pharmacol       Date:  1997-03-19       Impact factor: 4.432

8.  Caffeine enhances doxorubicin cardiac toxicity in an animal model.

Authors:  J D Hosenpud; J Wright; L Simpson; J J Abramson
Journal:  J Card Fail       Date:  1995-03       Impact factor: 5.712

9.  Transport mechanisms of idarubicin, an anthracycline derivative, in human leukemia HL60 cells and mononuclear cells, and comparison with those of its analogs.

Authors:  K Nagasawa; N Ohnishi; T Yokoyama
Journal:  Jpn J Cancer Res       Date:  1997-08

10.  Effects of 1-methyl-3-propyl-7-butylxanthine (MPBX) on idarubicin-induced antitumor activity and bone marrow suppression.

Authors:  Y Sadzuka; Y Egawa; T Sugiyama; H Sawanishi; K Miyamoto; T Sonobe
Journal:  Jpn J Cancer Res       Date:  2000-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.